Nucleoside Reverse Transcriptase Inhibitor (nrti) - Neonatal Disorders

Relevant Publications

HIV and adipose tissue: A long history linked to therapeutic classes of antiretrovirals.

Issue Release: 2024

Efficacy of Lamivudine Plus Dolutegravir vs Dolutegravir-Based 3-Drug Regimens in People With HIV Who Are Virologically Suppressed.

Issue Release: 2024

Impact of HIV self-testing for oral pre-exposure prophylaxis scale-up on drug resistance and HIV outcomes in western Kenya: a modelling study.

Issue Release: 2024

HIV-1 diversity and pre-treatment drug resistance in the era of integrase inhibitor among newly diagnosed ART-naïve adult patients in Luanda, Angola.

Issue Release: 2024

Influence of age and co-medication on dolutegravir glucuronidation in paediatric patients.

Issue Release: 2024

Low HIV drug resistance prevalence among recently diagnosed HIV-positive men who have sex with men in a setting of high PrEP use.

Issue Release: 2024

Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DF elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people living with HIV-1: the 48-week results of the SPRINT trial, a multi-centre, randomised, double-blind, active-controlled, phase 3, non-inferiority trial.

Issue Release: 2024

Prevalence of HIV Drug Resistance Mutations among Treatment-Naive People Living with HIV in a Tertiary Care Center in India.

Issue Release: 2024

Portable Nanopore sequencing solution for next-generation HIV drug resistance testing.

Issue Release: 2024

Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial.

Issue Release: 2024

Trends in HIV-1 pretreatment drug resistance and HIV-1 variant dynamics among antiretroviral therapy-naive Ethiopians from 2003 to 2018: a pooled sequence analysis.

Issue Release: 2023

HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis.

Issue Release: 2023

Human immunodeficiency virus 1 5\'-leader mutations in plasma viruses before and after the development of reverse transcriptase inhibitor-resistance mutations.

Issue Release: 2023

Genetic Diversity and Characteristics of Drug Resistance Among Treatment-Naive People Living with HIV in Xi\'an, China.

Issue Release: 2023

A National HIV Provider Survey of Antiretroviral Therapy Preferences for Management of Treatment-Naive and Experienced Individuals With Drug Resistance.

Issue Release: 2023

Comparative analysis of pre-existing HIV drug resistance mutations in proviral DNA via Next-Generation Sequencing and routine HIV RNA genotyping.

Issue Release: 2023

Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV.

Issue Release: 2023

Virologic status and pattern of drug resistance mutation among ART-experienced HIV-infected patients in Butuo: County, China.

Issue Release: 2023

Microglia and p38 MAPK Inhibitors Suppress Development of Mechanical Allodynia in Both Sexes in a Mouse Model of Antiretroviral-Induced Neuropathic Pain.

Issue Release: 2023

Strategies in the Design and Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs).

Issue Release: 2023

Why are Epigenetic Modifications Important in Pediatrics?

How is Genomic Data Interpreted?

What Does the Future Hold for Surfactant Replacement Therapy?

What Causes Insulin Resistance in Children?

How Can Parents Access PTIs?

Are There Any Safety Concerns When a Baby Starts Sitting Up?

How to Maintain and Update Your Professional Portfolio?

How Often Should Parents Read to Their Children?

What are the Clinical Signs of PMN Dysfunction in Children?

What are the Long-Term Implications for Infected Neonates?

Nucleoside Reverse Transcriptase Inhibitor (nrti) - Neonatal Disorders

Relevant Publications

Partnered Content Networks

Relevant Topics